This article was crafted with AI assistance.

Rickets — 7 Genes And 7 Biomarkers To Track

Introduction

If your child has been diagnosed with rickets — or if you are trying to understand why standard vitamin D supplementation is not producing results — you already know how frustrating it feels to get the same one-line answer at every appointment. Soft bones, bowed legs, delayed tooth eruption, and poor growth are visible and distressing. The explanation offered is almost always nutritional deficiency. That explanation is often correct, but it is rarely complete.

Rickets is not a single disease. It is a collection of conditions that converge on the same outcome — impaired bone mineralization — through very different mechanisms. Nutritional deficiency is the most common cause worldwide, but genetic mutations, impaired vitamin D metabolism, and abnormal phosphate regulation can each produce nearly identical clinical pictures while requiring entirely different interventions. Treating a child who has X-linked hypophosphatemic rickets the same way you would treat a child with dietary vitamin D deficiency does not work. It delays the right diagnosis, sometimes by years.

This is where tracking both biomarkers and genetic factors starts to matter in practical terms. Biomarkers reveal where the process is breaking down right now — in absorption, in enzymatic conversion, or in renal excretion. Genetic variants explain why the breakdown keeps happening regardless of what you supplement, and what the underlying architecture of the problem actually looks like.

This article covers both layers. The core section walks through the seven most informative biomarkers to test, what each one reveals about bone mineralization failure, how to measure it affordably, and what to do when a result falls outside the optimal range. A genetics section then covers the seven key genes most closely linked to rickets — with specific compensation strategies depending on whether you want to approach the problem with lifestyle changes alone or with clinical tools. Toward the end, you will find a summary of the most important research insights on vitamin D that most clinicians never mention, plus complementary approaches backed by human clinical evidence.

7 Biomarkers to Track for Rickets

Understanding rickets at the biomarker level is the most actionable starting point because blood tests are accessible, affordable, and repeatable. They give you direct feedback on whether an intervention is working. The seven biomarkers below were selected because they reflect the entire chain of events — from sun exposure and dietary intake, all the way through enzymatic activation, hormonal regulation, and final mineral deposition into bone. Together, they produce a complete metabolic picture that no single test can provide alone.

1. 25-Hydroxyvitamin D (25-OH Vitamin D)

Why it matters: This is the storage form of vitamin D and the standard clinical marker of vitamin D status. Low 25-OH D is the most common biochemical finding in nutritional rickets, and it directly impairs intestinal calcium absorption, leading to secondary hyperparathyroidism and progressive bone demineralization. It is also the first marker to normalize with supplementation, making it the essential tracking variable during treatment. Many clinicians consider the conventional cutoff of 20 ng/mL "sufficient," but for children with active rickets and for adults with bone disease, the functional target is substantially higher.

How to measure it: A standard serum blood test, orderable by any physician. Cost ranges from $30–$80 without insurance in the US, and it is included in many preventive care panels. Optimal levels for bone health are generally considered to be 40–60 ng/mL (100–150 nmol/L) by clinicians focused on metabolic optimization, such as Peter Attia and the GrassrootsHealth consortium, compared to the conventional "above 30 ng/mL" threshold. For children with active rickets, targets are typically higher — 40–60 ng/mL minimum during active treatment.

If the score is bad, the plan without supplements: Increase direct outdoor sun exposure. Fair-skinned individuals can produce 10,000–20,000 IU of vitamin D within 15–20 minutes of midday sun exposure covering a large skin surface area. Darker skin tones require 3–5 times longer. Glass blocks UVB radiation entirely — only outdoor time counts. Fatty fish (salmon, mackerel, sardines), egg yolks, and liver contribute modestly from diet. Magnesium repletion through food (leafy greens, pumpkin seeds, dark chocolate, black beans) is foundational because vitamin D activation requires magnesium at multiple enzymatic steps. Twenty to forty minutes of outdoor midday exposure daily, when the UV index is 3 or above, is the core non-supplement strategy.

If the score is bad, the plan with supplements or equipment: For confirmed deficiency with active rickets, the Endocrine Society recommends repletion doses of 2,000 IU/day of vitamin D3 for infants and up to 4,000–6,000 IU/day for older children, followed by a maintenance dose of 600–1,000 IU/day once levels normalize. Adults with deficiency typically require 5,000–10,000 IU/day to move levels meaningfully, depending on baseline and genetic factors. Always pair D3 with K2 in MK-7 form (100–200 mcg/day) to ensure calcium is directed toward bone rather than soft tissue. Retest at 8–12 weeks while titrating. UV-B home lamps (validated brands such as Sperti) can substitute for sunlight in climates with limited seasonal sun access. Side effects at doses above 10,000 IU/day: hypercalcemia is possible — monitor serum and urine calcium with any high-dose protocol. Holick et al. — Endocrine Society guidelines on vitamin D deficiency

2. 1,25-Dihydroxyvitamin D (Calcitriol)

Why it matters: Calcitriol is the biologically active form of vitamin D, produced in the kidneys by the enzyme 1-alpha-hydroxylase, encoded by the CYP27B1 gene. While 25-OH D reflects storage status, calcitriol reflects active hormonal output. In type 1 vitamin D-dependent rickets (VDDR1), the 25-OH D level can appear normal or elevated while calcitriol is critically low — because the enzymatic conversion step is missing. Treating this with standard vitamin D supplementation adds more substrate to a broken pathway and accomplishes nothing. In type 2 VDDR, calcitriol is paradoxically elevated because the receptor cannot respond to it. Without this test, these two scenarios are routinely misclassified.

How to measure it: Ordered specifically as "1,25-dihydroxyvitamin D" or "calcitriol" through a specialty or endocrinology lab — it is not always included in standard vitamin D panels. Cost ranges from $80–$150 and typically requires physician ordering. It must always be interpreted alongside 25-OH D and PTH to triangulate the location of impairment in the vitamin D pathway. Reference range is generally 18–72 pg/mL, but interpretation in the context of suspected genetic rickets requires specialist involvement.

If the score is bad, the plan without supplements: There is no dietary or lifestyle strategy that reliably raises calcitriol when the underlying enzymatic pathway is impaired. If CYP27B1 function is compromised, the kidneys cannot convert the precursor regardless of how much substrate is available. The non-supplement priority here is identifying the cause — which means ordering genetic testing for CYP27B1 and CYP2R1 variants. For carriers (one abnormal copy) with partial function, maximizing the 25-OH D substrate to 50–70 ng/mL gives the impaired enzyme the best possible working conditions.

If the score is bad, the plan with supplements or equipment: When calcitriol is low due to 1-alpha-hydroxylase deficiency (VDDR1), treatment is pharmaceutical calcitriol (Rocaltrol), which bypasses the enzymatic step entirely. Typical doses are 0.25–2 mcg/day, titrated under endocrinological supervision. Calcium supplementation (500–1,000 mg elemental calcium/day) is added concurrently. This is prescription territory — do not use over-the-counter calcitriol analogs without clinical oversight. Regular monitoring of serum and urinary calcium is mandatory because calcitriol is much more potent than standard vitamin D3 and hypercalcemia risk is real at inappropriately high doses.

3. Parathyroid Hormone (PTH)

Why it matters: PTH is the body's calcium-rescue hormone. When vitamin D and dietary calcium are insufficient, PTH rises to extract calcium from bones, enhance renal calcium reabsorption, and stimulate calcitriol synthesis. In nutritional rickets, elevated PTH is virtually always present and is one of the primary drivers of progressive bone damage. PTH normalizes more slowly than 25-OH D during treatment, making it one of the most reliable indicators of true biological recovery — a PTH trending toward normal tells you the underlying calcium economy is genuinely stabilizing, not just that serum vitamin D was artificially pushed up by supplementation. A persistently elevated PTH despite corrected vitamin D signals something deeper: inadequate calcium intake, genetic impairment, or underlying kidney disease.

How to measure it: Intact PTH is a standard serum test, costing $30–$80 and included in many specialty panels. Optimal range is 10–55 pg/mL; values persistently above 65–70 pg/mL in the context of low-normal or low calcium should be considered secondary hyperparathyroidism until fully evaluated. Interpret always alongside total calcium, phosphate, and 25-OH D.

If the score is bad, the plan without supplements: The first non-supplement intervention is calcium adequacy from food: 1,000–1,300 mg/day of elemental calcium from dairy, fortified plant milks, small fish eaten with bones, and dark leafy greens. Phytate intake from unsoaked grains and legumes reduces calcium absorption by up to 30% — soaking and sprouting grains before cooking reduces phytate content significantly. Correcting vitamin D through sun exposure simultaneously suppresses PTH by reducing calcium deficiency signaling. Twenty to thirty minutes of outdoor midday sun daily is the best single combined intervention.

If the score is bad, the plan with supplements or equipment: Vitamin D3 (dosed based on 25-OH D levels as above) plus calcium citrate (citrate form is better absorbed than carbonate, especially in individuals with reduced stomach acid, which includes many children on long-term proton pump inhibitors). Magnesium glycinate or malate, 300–400 mg/day, supports PTH regulation and improves the vitamin D response at the receptor level. PTH should normalize within 3–6 months of adequate repletion if the cause is nutritional. If it remains elevated after correction of vitamin D and calcium, investigate kidney function, measure FGF23, and pursue genetic evaluation.

4. Serum Phosphate

Why it matters: Phosphate is the second structural mineral essential for bone mineralization. Hypophosphatemia — low serum phosphate — is the defining biochemical feature of X-linked hypophosphatemic rickets (XLH), the most common hereditary form of the disease, affecting approximately 1 in 20,000 individuals globally. In XLH, phosphate is wasted by the kidneys due to chronically elevated FGF23 driven by a PHEX mutation. Standard vitamin D supplementation does not address this problem at all. Children with XLH who receive only vitamin D treatment may have their 25-OH D normalized but their bones continue to deteriorate because the phosphate deficit is untouched. Recognizing hypophosphatemia in the context of normal or low PTH is the biochemical signal that points toward hereditary rather than nutritional rickets.

How to measure it: Serum phosphate is included in most comprehensive metabolic panels ($20–$50), but it must be drawn fasting — a high-carbohydrate meal temporarily lowers phosphate as insulin drives it into cells, creating a false appearance of hypophosphatemia. Normal fasting range in adults is 2.5–4.5 mg/dL; children have higher physiological values (3.0–6.0 mg/dL), making adult-range normal values actually low for a child. A tubular maximum phosphate reabsorption corrected for GFR (TmP/GFR) — measured with simultaneous urine and serum phosphate — is more sensitive for detecting renal phosphate wasting even when fasting serum levels appear borderline.

If the score is bad, the plan without supplements: In nutritional rickets, phosphate normalizes as vitamin D and calcium deficiencies are corrected and PTH falls. Dietary phosphate is abundant in most diets (meat, dairy, legumes, nuts) and pure dietary phosphate deficiency is rare in developed countries. However, excess consumption of phosphoric acid-containing sodas alongside chronically low dairy intake creates an unfavorable calcium-to-phosphate ratio that modestly worsens bone mineralization. Removing processed foods with phosphate additives and ensuring adequate dietary protein are sensible baseline interventions for any child with borderline phosphate.

If the score is bad, the plan with supplements or equipment: For XLH and other phosphate-wasting disorders, the traditional treatment is oral phosphate supplementation (20–40 mg/kg/day in 4–5 divided doses throughout the day) plus activated vitamin D (calcitriol). The dosing frequency is burdensome and GI side effects including diarrhea are common. A newer FDA-approved biologic — burosumab (Crysvita), a monoclonal antibody that neutralizes FGF23 — has become the preferred first-line therapy for children with confirmed XLH. Clinical trials demonstrated significant improvements in rickets severity scores, phosphate levels, and linear growth within 40 weeks. Carpenter et al. — Burosumab versus conventional therapy for X-linked hypophosphatemia, NEJM 2018

5. Serum Calcium

Why it matters: Calcium is the dominant structural mineral of bone, and its serum level is defended with extraordinary biological priority. The body will dissolve bone to maintain serum calcium in range — which means serum calcium can appear normal even when bone demineralization is well advanced. This makes total serum calcium a somewhat blunt marker in isolation, but it remains essential for interpreting the calcium-PTH-vitamin D triad. Ionized calcium — the unbound, biologically active fraction — is more precise and is not affected by albumin levels or dehydration. In any child with rickets, a low ionized calcium confirms active calcium deficiency, while a normal ionized calcium shifts suspicion toward a phosphate or enzymatic problem.

How to measure it: Total serum calcium is included in basic metabolic panels ($20–$50). Ionized calcium requires a separate test ($40–$80) and is more informative for nuanced cases. Optimal total calcium is 9.0–10.5 mg/dL; optimal ionized calcium is 1.15–1.35 mmol/L. Albumin-corrected calcium is a useful intermediate calculation when total calcium and albumin are both known.

If the score is bad, the plan without supplements: Dietary calcium optimization is the core intervention: 1,000–1,300 mg/day from real food sources. Full-fat dairy provides calcium alongside fat-soluble vitamins A and K2, which are synergistic. Calcium absorption depends on stomach acid — chronically suppressed acid (from antacids or PPIs) meaningfully impairs calcium uptake. Cooking oxalate-rich greens (spinach, beet greens) by boiling and discarding water reduces oxalate content by up to 50%, improving calcium bioavailability. Ensuring adequate protein intake maintains the hormonal and mechanical signals that drive calcium into bone.

If the score is bad, the plan with supplements or equipment: Calcium citrate (500 mg elemental calcium, twice daily between meals) is the preferred form for supplementation — better absorbed than carbonate in low-acid environments and at meals. Do not exceed 500 mg per dose, as absorption efficiency drops sharply at higher single doses. Combine with vitamin D3 and K2. Retest at 8–12 weeks. If hypocalcemia is symptomatic (muscle cramps, tetany, paresthesias, or seizures), this is a medical emergency requiring intravenous calcium in a hospital setting — oral supplementation is insufficient for acute hypocalcemia.

6. Alkaline Phosphatase (ALP)

Why it matters: Alkaline phosphatase is an enzyme released by active osteoblasts during their effort to mineralize bone matrix. In active rickets, ALP is often markedly elevated — osteoblasts are working intensely but failing because calcium and phosphate are inadequate. ALP elevation is one of the most sensitive markers for active bone disease and begins to normalize within weeks of effective treatment, making it an excellent real-time treatment response marker. However, ALP occupies a unique dual diagnostic role in bone disease: where elevated ALP signals classic rickets, very low ALP signals hypophosphatasia (HPP) — a genetic condition caused by ALPL mutations that produces a rickets-like picture through the exact opposite mechanism. Confusing these two leads to profoundly wrong treatment decisions.

How to measure it: ALP is included in standard liver function and metabolic panels ($20–$60). Important: ALP has liver and bone isoforms, and total ALP can be elevated from either source. If liver function tests are otherwise normal in a child with rickets, elevated ALP is almost certainly bone-origin. Bone-specific ALP can be ordered separately ($80–$120) when the source is uncertain. Use age-specific pediatric reference ranges — normal ALP in a growing child is substantially higher than in adults, and adult reference ranges will falsely flag normal pediatric values as abnormal.

If the score is bad, the plan without supplements: Elevated ALP in rickets normalizes as the underlying deficiency is corrected — it is a consequence of the disease, not a separate target. The foundational interventions are identical to those for 25-OH D and calcium. Tracking ALP serially over 2–3 months of treatment is one of the most practical ways to confirm that bone biology is actually improving, not just that lab numbers shifted.

If the score is bad, the plan with supplements or equipment: For elevated ALP, vitamin D3 and calcium repletion as outlined above. For low ALP — the hallmark of hypophosphatasia — the approach is fundamentally different. Enzyme replacement therapy with asfotase alfa (Strensiq) is FDA-approved and shown to significantly improve bone mineralization, respiratory function, and motor development in pediatric HPP. Whyte et al. — Asfotase alfa for perinatal and infantile hypophosphatasia, NEJM 2012 In HPP, standard vitamin D and calcium supplementation can paradoxically worsen the condition by increasing calcium and phosphate without the enzymatic machinery to incorporate them into bone — making the differential diagnosis critical before starting any treatment.

7. FGF23 (Fibroblast Growth Factor 23)

Why it matters: FGF23 is a phosphate-regulatory hormone produced primarily in osteocytes. It signals the kidneys to excrete phosphate and simultaneously suppresses calcitriol production. In X-linked hypophosphatemic rickets, PHEX mutations allow FGF23 to accumulate in excess, driving chronic renal phosphate wasting. FGF23 is not routinely included in standard metabolic panels, and most general practitioners never order it — but it is the single most important biomarker for distinguishing phosphate-wasting hereditary rickets from nutritional rickets. An elevated FGF23 combined with low serum phosphate and normal PTH is essentially diagnostic of a hereditary phosphate-wasting disorder. Finding this pattern early changes treatment and potentially prevents permanent skeletal deformity.

How to measure it: Intact FGF23 requires a specialized assay not included in standard chemistry panels. It is typically ordered through endocrinology, nephrology, or metabolic genetics departments. Cost ranges from $150–$300. Blood must be processed quickly and plasma frozen promptly, as FGF23 degrades rapidly at room temperature — collection technique affects accuracy. Reference values for intact FGF23 are generally below 100 pg/mL; in active XLH or other FGF23-excess disorders, levels typically exceed 150–400 pg/mL.

If the score is bad, the plan without supplements: For hereditary FGF23 excess, lifestyle changes cannot normalize the underlying hormonal overproduction. Dietary phosphate restriction has limited impact and may compromise bone building. The most important non-pharmacological priority is confirming the diagnosis genetically (PHEX, FGF23, or FGFR1 sequencing) so that treatment is directed correctly. Physical therapy and orthopedic monitoring to manage skeletal deformities, dental surveillance (XLH causes spontaneous tooth abscesses from defective dentin), and avoidance of excessive dietary phosphate additives in processed foods are the practical daily measures.

If the score is bad, the plan with supplements or equipment: Burosumab (Crysvita) — subcutaneous injection every 2 weeks in children and every 4 weeks in adults — is now the standard of care for XLH and is effective for any FGF23-excess disorder. It directly neutralizes FGF23, allowing phosphate to rise and calcitriol synthesis to normalize. Where burosumab is unavailable due to cost or access, traditional oral phosphate supplementation plus calcitriol is the alternative, though the dosing burden and side effect profile are less favorable. Imel et al. — Iron deficiency and elevated FGF23 in autosomal dominant hypophosphatemic rickets

With the full biomarker picture established, it is worth understanding the genetic architecture underneath it — because biomarker abnormalities in rickets are rarely random. They follow predictable patterns determined by which gene is impaired.

7 Genes Linked to Rickets and Bone Mineralization

Genetic variants in the following genes explain why some individuals develop rickets despite adequate nutrition, why others fail to respond to standard vitamin D supplementation, and why some families see rickets appear across multiple generations. Knowing your genetic profile does not eliminate the problem, but it directs the solution far more precisely than chasing biomarkers alone.

VDR (Vitamin D Receptor)

What it affects: VDR encodes the nuclear receptor through which active vitamin D (calcitriol) exerts its effects across virtually every tissue type — including intestinal calcium absorption, bone remodeling, immune regulation, and muscle function. Several common SNPs in VDR have been extensively studied: the FokI variant (rs2228570) reduces transcriptional efficiency, meaning carriers need higher circulating calcitriol to achieve the same biological effect. The BsmI, ApaI, and TaqI variants affect VDR expression levels and mRNA stability. Individuals carrying VDR efficiency variants may present as "vitamin D resistant" — technically normal serum levels but poor biological response — and require higher target 25-OH D levels to achieve adequate VDR activation. Uitterlinden et al. — VDR gene polymorphisms in disease

If the gene is bad, the plan without supplements: Maximize sun exposure to drive 25-OH D levels to the upper end of optimal (50–70 ng/mL) — higher substrate partially compensates for lower receptor efficiency. Daily weight-bearing outdoor activity (walking, jumping, sport) activates the mechano-osteogenic Wnt/β-catenin pathway independently of VDR, supporting bone density through a parallel route. Ensure dietary calcium at the high end of recommended intake (1,200–1,300 mg/day from food). Reduce inflammatory dietary load (ultra-processed food, excess omega-6 vegetable oils) because systemic inflammation downregulates VDR expression through NF-κB signaling, worsening the receptor-efficiency problem.

If the gene is bad, the plan with supplements: Target higher 25-OH D levels than the standard recommendation: 50–70 ng/mL rather than just above 30 ng/mL. This typically requires 5,000–10,000 IU/day of vitamin D3 in VDR variant carriers, titrated by blood testing every 12 weeks. Pair with K2 (MK-7 form, 200 mcg/day) to direct calcium appropriately. Magnesium glycinate (400 mg/day) is a required cofactor for calcitriol synthesis and for VDR activation. Retinol (preformed vitamin A, not beta-carotene) at 5,000 IU/day may synergize with VDR through shared nuclear receptor pathways — use retinol form and avoid megadoses above 10,000 IU/day (teratogenic risk and potential toxicity). Retest serum calcium at high D3 doses to monitor for hypercalcemia. Cycling: supplementation is continuous for this indication; reduce to maintenance after levels stabilize, then retest seasonally.

CYP27B1 (1-Alpha-Hydroxylase)

What it affects: CYP27B1 encodes the mitochondrial enzyme that converts 25-OH vitamin D into calcitriol (active vitamin D) in the kidney. Loss-of-function mutations cause VDDR type 1A — a rare autosomal recessive condition where rickets develops in the first year of life despite normal dietary vitamin D and adequate 25-OH D levels. Calcitriol is severely deficient because the conversion step is absent. Heterozygous carriers (one abnormal copy) show subclinical impairment in vitamin D activation — they may require substantially higher 25-OH D levels to generate adequate calcitriol output. Inflammatory conditions and aging also reduce CYP27B1 activity, making this enzyme a convergence point between genetics and environment.

If the gene is bad, the plan without supplements: The enzyme is the problem, so no dietary strategy can meaningfully substitute for a non-functional CYP27B1. For carriers with partial function, maximizing the substrate — targeting 25-OH D above 60 ng/mL — gives the impaired enzyme the best conditions to work with. Reducing systemic inflammation through an anti-inflammatory diet (abundant omega-3 fatty acids from fatty fish, low ultra-processed food, polyphenol-rich plants) has biochemical rationale: pro-inflammatory cytokines, particularly TNF-alpha and IL-1, directly suppress CYP27B1 gene expression. Managing any concurrent autoimmune or chronic inflammatory condition therefore supports CYP27B1 function.

If the gene is bad, the plan with supplements: For confirmed VDDR1 with CYP27B1 loss-of-function, pharmaceutical calcitriol (Rocaltrol, 0.25–2 mcg/day) bypasses the enzymatic defect entirely and is the definitive treatment. This is prescription-only and requires pediatric endocrinology management with frequent serum and urine calcium monitoring. For carriers with subclinical impairment, calcifediol (25-hydroxyvitamin D3 as Rayaldee, or OTC forms available in some markets) can be considered as it requires only the final enzymatic conversion step rather than both. Magnesium (400 mg/day) is non-negotiable as a CYP27B1 cofactor. Side effects of calcitriol: hypercalcemia risk at inappropriate doses — urine calcium monitoring every 3 months.

CYP2R1 (25-Hydroxylase)

What it affects: CYP2R1 encodes the primary enzyme responsible for adding the initial 25-hydroxy group to vitamin D in the liver — the first step in the two-step activation cascade. Mutations cause VDDR type 1B, a milder deficiency state in which vitamin D intake and sun exposure do not efficiently translate into measurable 25-OH D levels. Carriers of common CYP2R1 variants (including rs10741657) may require 2–3 times the supplemental vitamin D dose of a typical person to achieve equivalent 25-OH D levels. This variant is clinically significant because such individuals often appear vitamin D-deficient on blood tests despite seemingly adequate intake — and clinicians without genetic context may simply keep increasing the dose without understanding why it is not working. Nissen et al. — CYP2R1 variants and response to vitamin D supplementation

If the gene is bad, the plan without supplements: Liver health optimization reduces the enzymatic bottleneck — chronic alcohol use, excess fructose consumption, and environmental toxin exposure reduce hepatic CYP2R1 function over time. A whole-food diet with abundant cruciferous vegetables (which upregulate hepatic enzyme activity), moderate protein, and minimal ultra-processed food supports liver-phase vitamin D conversion. Fatty fish consumption (salmon, mackerel, herring) provides vitamin D3 directly in a form that still reduces the CYP2R1 burden compared to conversion from D2.

If the gene is bad, the plan with supplements: High-dose D3 (5,000–10,000 IU/day) with 8-week serum testing is required — the goal is to confirm that 25-OH D levels actually rise, not just to assume they do. If 10,000 IU/day of D3 fails to bring 25-OH D above 40 ng/mL consistently, calcifediol (pharmaceutical or OTC 25-OH D3) is the solution — it bypasses CYP2R1 entirely since it is already the 25-hydroxylated form. In confirmed CYP2R1 dysfunction, this is a rational clinical pivot that many practitioners have not considered. Retest every 8 weeks while adjusting doses; monitor calcium as above.

PHEX (Phosphate-Regulating Endopeptidase)

What it affects: PHEX mutations cause X-linked hypophosphatemic rickets (XLH), the most common hereditary rickets, with a prevalence of 1 in 20,000 births. PHEX encodes a protease that normally degrades ASARM peptides (which inhibit mineralization) and regulates FGF23. When PHEX is non-functional, FGF23 accumulates excessively, signaling the kidneys to waste phosphate — resulting in chronic hypophosphatemia despite adequate dietary phosphate intake. XLH is X-linked dominant: females with one abnormal copy develop disease, though males are typically more severely affected. Classic features include bowed legs, short stature, bone pain, and spontaneous dental abscesses from defective dentin — a hallmark that should prompt genetic evaluation in any child with unexplained dental pathology.

If the gene is bad, the plan without supplements: A phosphate-rich diet does not compensate for the scale of renal phosphate wasting in XLH. However, eliminating processed foods with phosphate additives reduces the FGF23 stimulus modestly. Weight-bearing physical activity (swimming is insufficient for bone loading; walking, jumping, and resistance exercise are needed) is essential for maintaining bone density and muscle strength alongside medical treatment. Regular dental surveillance every 6 months and prompt treatment of dental infections reduce complications. Physical therapy for gait and postural issues reduces secondary musculoskeletal burden.

If the gene is bad, the plan with supplements or equipment: Burosumab (Crysvita) is now first-line for confirmed PHEX mutations, administered subcutaneously every 2 weeks in children and every 4 weeks in adults. Where burosumab is not accessible, traditional therapy is neutral phosphate solution (20–40 mg/kg/day in 4–5 divided doses) plus calcitriol (20–30 ng/kg/day). Nephrocalcinosis — calcium deposits in the kidneys — is a significant complication of long-term conventional phosphate/calcitriol therapy that requires periodic renal ultrasound monitoring. Orthopedic surgery may be necessary for severe leg deformities. Growth hormone has been used adjunctively in children with significantly impaired linear growth.

FGF23 (Fibroblast Growth Factor 23)

What it affects: While PHEX mutations cause FGF23 excess indirectly, activating mutations of the FGF23 gene itself cause autosomal dominant hypophosphatemic rickets (ADHR) — a condition with variable and sometimes delayed penetrance. A biochemically unique feature of ADHR is its interaction with iron status: iron deficiency stabilizes the FGF23 protein and prevents its cleavage and inactivation. This means that an ADHR patient can remain relatively asymptomatic when iron-replete but deteriorate dramatically during periods of iron deficiency — such as in adolescent females during heavy menstrual periods or in pregnancy. This iron-FGF23 axis is one of the most practical and actionable recent findings in hereditary rickets research.

If the gene is bad, the plan without supplements: Dietary iron optimization is the foundational non-supplement intervention for ADHR specifically. Iron-rich whole foods — red meat and organ meats (heme iron, best absorbed), dark leafy greens and legumes consumed with vitamin C-rich foods (enhances non-heme iron absorption) — support FGF23 regulation. Cooking in cast iron cookware modestly increases iron content of acidic foods. Investigating and treating any source of iron loss (heavy menstruation, GI bleeding, occult blood loss) is a clinical priority. Avoiding tea, coffee, and calcium supplements at meals (all reduce non-heme iron absorption) on iron-load days can optimize dietary iron uptake.

If the gene is bad, the plan with supplements or equipment: Iron supplementation — ferrous bisglycinate is the best-tolerated oral form (25–50 mg elemental iron, taken with vitamin C to enhance absorption, away from calcium and magnesium) — has demonstrated ability to reduce FGF23 levels and improve phosphate in iron-deficient ADHR patients. Cycling: treat iron deficiency with therapeutic doses until ferritin normalizes (target 50–100 ng/mL), then maintain with lower ongoing doses if dietary intake remains insufficient. Burosumab applies equally to FGF23-excess from ADHR as from XLH. Side effects of iron: constipation is common — magnesium or psyllium co-supplementation helps; nausea is minimized by taking with food.

ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1)

What it affects: ENPP1 encodes an enzyme that generates inorganic pyrophosphate (PPi) — a natural inhibitor of pathological mineralization. The ENPP1/AMP/adenosine pathway is now recognized as a central regulator of the balance between bone mineralization and ectopic calcification. Loss-of-function ENPP1 mutations cause hypophosphatemia (via reduced production of extracellular AMP, which feeds into the TNAP pathway that is needed for normal bone mineralization) and a rickets-like syndrome with paradoxical calcification in soft tissues. ENPP1 is not yet included on most standard genetic panels for rickets, but it should be considered in any case where PHEX, VDR, CYP27B1, and FGF23 testing is unrevealing.

If the gene is bad, the plan without supplements: Avoiding high-dose calcium supplementation is important when ENPP1 regulation is impaired, as excess calcium substrate without adequate PPi control can worsen ectopic calcification. A diet low in inorganic phosphate additives (found in processed meats, packaged baked goods, and many soft drinks) reduces the substrate burden on the dysregulated pathway. Regular physical activity supports bone remodeling through mechanical signaling pathways that are at least partially ENPP1-independent.

If the gene is bad, the plan with supplements or equipment: Enzyme replacement therapy for ENPP1 deficiency (ENPP1-Fc fusion protein, currently in clinical trials under the name INZ-701/inozyme) has shown early promising results in normalizing PPi and pyridoxal-5'-phosphate levels in pediatric cases. For milder ENPP1 variants contributing to hypophosphatemia, the same phosphate and calcitriol protocols used in XLH can be applied. This is a rare condition requiring subspecialty management at a metabolic bone center. Avoid high-dose vitamin D without confirming phosphate status, as vitamin D can drive mineralization into soft tissues when PPi regulation is impaired.

ALPL (Alkaline Phosphatase Liver/Bone/Kidney)

What it affects: Loss-of-function mutations in ALPL cause hypophosphatasia (HPP) — a metabolic bone disease that mimics rickets on X-ray but represents its biochemical mirror image. Where rickets involves insufficient mineralization from lack of calcium and phosphate, HPP involves insufficient mineralization from deficiency of the enzyme that removes the pyrophosphate brake. Without adequate ALP, pyrophosphate, pyridoxal-5'-phosphate (vitamin B6), and phosphoethanolamine accumulate, preventing normal bone and tooth mineralization despite normal serum calcium and phosphate levels. Premature loss of baby teeth before age 5 (with intact roots) is one of the most specific HPP clinical signs. Giving standard rickets treatment — vitamin D and calcium — to a child with HPP not only fails to help but can cause hypercalcemia. This distinction is not a clinical nicety. It is the difference between appropriate care and iatrogenic harm.

If the gene is bad, the plan without supplements: Avoid vitamin D loading and high-dose calcium supplementation — both are standard rickets treatments that are contraindicated in HPP. Vitamin B6 supplementation is also unnecessary and potentially counterproductive, as pyridoxal-5'-phosphate is already elevated as an accumulated substrate. Protective footwear, activity modification to reduce fracture risk, and regular orthopedic monitoring are the practical daily measures. Physical therapy to maintain muscle strength and gait without high-impact loading is important.

If the gene is bad, the plan with supplements or equipment: Asfotase alfa (Strensiq) is FDA-approved enzyme replacement therapy for perinatal, infantile, juvenile, and adult HPP. Given subcutaneously (1–3 mg/kg 3x/week for severe cases), it has substantially improved survival, respiratory function, and bone mineralization in clinical trials for severe pediatric HPP. Bisphosphonates — often prescribed empirically for bone fragility — are strictly contraindicated in HPP (they further inhibit ALP activity). For adults with mild HPP presenting primarily as stress fractures, monitoring without asfotase may be appropriate. Management requires a physician experienced with HPP, as the treatment and monitoring protocols differ fundamentally from every other rickets subtype.

The table below summarizes the key actions for each gene and biomarker at a glance.

10 Things the Research on Vitamin D May Change About How You Think

Rhonda Patrick's vitamin D research, which has been prominently featured across multiple Huberman Lab podcast appearances and her own FoundMyFitness platform, synthesizes decades of molecular biology with practical clinical relevance in ways that most medical appointments never reach. The following ten points are among the most evidence-dense and practically useful takeaways for anyone navigating rickets or chronic vitamin D insufficiency.

1. Vitamin D Functions as a Master Regulatory Hormone, Not a Vitamin

Every cell in the human body contains a VDR receptor. Calcitriol regulates more than 1,000 gene expression patterns, including immune cell development, insulin sensitivity, neuromuscular function, and vascular health. The conventional framing as a "bone vitamin" represents about 5% of its actual biological function. For rickets specifically, this means that treating vitamin D deficiency is not just about the bones — it is about restoring a hormonal system that affects the entire organism.

2. The "Sufficient" Cutoff Was Set to Prevent Rickets, Not to Optimize Health

The conventional laboratory threshold of 20 ng/mL for vitamin D sufficiency was established based on the minimum level needed to prevent frank rickets and osteomalacia in adults. It was never derived from data on optimal immune function, cancer prevention, metabolic health, or cognitive performance. Researchers including Rhonda Patrick and the GrassrootsHealth network propose that 40–60 ng/mL is the range most consistent with the physiological conditions under which humans evolved, as inferred from outdoor-working populations.

3. Magnesium Deficiency Blocks Vitamin D Activation at Multiple Steps

Magnesium is a required cofactor for vitamin D-binding protein, for CYP27B1, and for VDR itself. Supplementing vitamin D without adequate magnesium can create a situation in which serum 25-OH D rises but biological activity does not — the substrate accumulates without being converted to useful calcitriol. Approximately 50% of the US population is estimated to be magnesium-insufficient by red blood cell magnesium criteria. Checking and correcting magnesium before titrating vitamin D doses is a step most protocols omit but that can explain non-response to supplementation.

4. Vitamin K2 Is Non-Negotiable When Supplementing Calcium and Vitamin D

Vitamin K2 (particularly MK-7) activates osteocalcin (which binds calcium into bone matrix) and matrix GLA protein (which prevents calcium from depositing in arteries and soft tissue). Supplementing vitamin D and calcium without K2 increases circulating calcium without providing the directional signals needed to guide it to bone. This is not theoretical — observational studies link K2 intake to reduced arterial calcification and improved bone mineral density. The MK-7 form has a 72-hour half-life (versus 4–6 hours for MK-4), making once-daily dosing effective.

5. Glass Blocks UVB — Indoor Sunlight Does Not Produce Vitamin D

Only the UVB band (280–315 nm) triggers vitamin D synthesis in skin. Glass efficiently blocks UVB while transmitting UVA. Sitting by a window in sunlight does not generate any vitamin D, regardless of how bright or warm it feels. This is clinically relevant for housebound individuals, infants in carriages covered with covers, and people in cold climates who get "sun" primarily through windows. For any family managing vitamin D deficiency, this single fact changes the practical guidance substantially.

6. Skin Pigmentation, Latitude, and Seasonality Create Compounding Deficiency Risk

Melanin acts as a natural sunscreen, reducing UVB penetration into deeper skin layers where vitamin D synthesis occurs. Individuals with darker skin types (Fitzpatrick types V–VI) may require 3–10 times longer UV exposure to generate equivalent vitamin D as fair-skinned individuals. At latitudes above 37°N (above San Francisco, Rome, or Seoul), UVB intensity between November and March is insufficient to drive meaningful vitamin D production regardless of skin type. These factors compound — a dark-skinned infant in a northern city in winter has virtually no solar vitamin D supply, which is why nutritional rickets persists in this demographic in otherwise wealthy countries.

7. Omega-3 Fatty Acids Enhance Vitamin D Absorption and VDR Expression

Vitamin D is fat-soluble and its intestinal absorption is substantially influenced by concurrent fat intake. Omega-3 fatty acids, beyond their role in fat-soluble vitamin absorption, have been shown in cell culture and animal studies to upregulate VDR expression — particularly the EPA and DHA forms found in fatty fish. Taking vitamin D supplements with a fat-containing meal (ideally containing omega-3 rich foods) meaningfully improves absorption. This practical point is often missed in supplementation protocols that recommend taking vitamin D in the morning on an empty stomach.

8. Gut Health Affects Vitamin D Metabolism Through Bile Acid Signaling

Bile acids, produced by intestinal bacteria from cholesterol, interact with the farnesoid X receptor (FXR) pathway in ways that modulate VDR signaling. Dysbiosis — reduced gut microbial diversity — is associated with lower vitamin D bioavailability and impaired VDR activation in emerging research. This connection may partially explain why individuals with inflammatory bowel disease, celiac disease, or a history of antibiotic use often show persistent vitamin D insufficiency despite supplementation. Restoring gut microbiome diversity through fermented foods, prebiotic fiber, and avoidance of unnecessary antibiotics is a biologically rational support strategy.

9. Sunscreen Application Timing Matters More Than Most Guidelines Acknowledge

Most sunscreen guidance recommends applying sunscreen before going outdoors. Consistent pre-exposure application essentially eliminates UVB-driven vitamin D synthesis. An emerging evidence-based approach for individuals who are vitamin D-insufficient is to allow 10–30 minutes of unprotected midday sun exposure (calibrated to skin tone and UV index) before applying sunscreen, rather than applying it preventively from the start. The risk of significant DNA damage from 10–20 minutes of moderate-UV exposure in a vitamin D-deficient individual appears to be substantially outweighed by the metabolic benefit, though this calculus changes significantly with high UV index and fair skin.

10. Weight-Bearing Exercise Drives Bone Mineralization Through a VDR-Independent Pathway

Mechanical loading on bone activates the Wnt/β-catenin and mTOR pathways in osteoblasts, stimulating new bone formation through entirely separate mechanisms from vitamin D signaling. This means that even individuals with VDR variants, CYP27B1 impairment, or moderate vitamin D insufficiency can partially offset bone density loss through regular weight-bearing activity. For children with rickets undergoing medical treatment, daily physical activity involving jumping, running, and resistance activities is not just good general health advice — it is an active therapeutic intervention that complements and extends the effects of supplementation and medication.

Complementary Approaches With Meaningful Evidence for Bone Mineralization

The following modalities were selected because they have human clinical evidence that is specifically relevant to rickets, vitamin D metabolism, or bone health. They are meant to complement, not replace, the medical and nutritional interventions described above.

Light Therapy (UV-B Phototherapy)

UV-B phototherapy is a narrow-band light treatment traditionally used for skin conditions such as psoriasis, but its most basic biological action is precisely the mechanism by which skin produces vitamin D3 — UVB photons converting 7-dehydrocholesterol in the epidermis into pre-vitamin D3. For individuals who cannot achieve adequate sun exposure due to geography, photosensitivity, disability, or institutionalization, medical-grade UV-B lamps provide a controlled and reproducible alternative. This is directly relevant to rickets in low-sunlight populations, individuals with dark skin in northern latitudes, and children whose mobility limits outdoor time.

A randomized controlled study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that narrow-band UV-B phototherapy in vitamin D-deficient adults significantly raised 25-OH D levels and was well tolerated. Validated home UV-B devices (Sperti Fiji Sun or medical-grade units prescribed by a dermatologist) deliver UVB in calibrated doses. Session duration depends on skin type and UV lamp output — starting at 30–60 second exposures and building gradually is the standard protocol.

For practical application in a rickets context, a UV-B lamp used 3–4 times per week during winter months or year-round in high-latitude climates provides a measurable vitamin D contribution. It does not fully replace supplementation for significant deficiency states but reduces the supplement dose required and provides the natural D3 form identical to sun-derived production. Begin with short sessions and monitor 25-OH D levels at 8-week intervals to track response. Individuals with photosensitivity conditions or those on photosensitizing medications should consult a dermatologist before starting.

Microbiome-Directed Therapies

The gut microbiome influences the bioavailability of calcium, phosphate, and vitamin D through multiple mechanisms: bile acid metabolism, short-chain fatty acid production (which maintains gut barrier integrity and reduces inflammatory signals that suppress CYP27B1), and direct modulation of VDR expression in intestinal epithelium. In conditions of intestinal dysbiosis — including antibiotic overuse, inflammatory bowel disease, and low-fiber diets — these functions are impaired, and nutritional rickets can persist despite seemingly adequate supplementation. Microbiome-directed therapy includes dietary fiber intake, fermented food consumption, and targeted probiotic use.

A meta-analysis examining probiotic supplementation and bone mineral density found that specific Lactobacillus and Bifidobacterium strains improved calcium absorption markers and reduced bone resorption biomarkers in postmenopausal women with low bone density (Wang et al., Frontiers in Endocrinology, 2020). While direct evidence in pediatric rickets is limited, the mechanistic pathway is well-established and the interventions are low-risk. Kefir and yogurt with live cultures provide both calcium and probiotic organisms simultaneously, making them particularly well-suited as daily dietary additions for children with rickets.

Practically, a daily intake of 25–35g of diverse dietary fiber (from vegetables, legumes, whole grains, and fruit), combined with 1–2 servings of fermented foods (yogurt, kefir, sauerkraut, kimchi), provides the substrate for microbiome diversity without requiring supplementation. For targeted probiotic support, Lactobacillus rhamnosus GG and Bifidobacterium longum have the strongest human evidence for intestinal barrier function. A 12-week course with reassessment is a reasonable initial protocol. This is genuinely supportive, not curative — but it addresses an often-ignored variable in why some children respond better to supplementation than others.

Yoga

Yoga may seem like an unlikely entry in a rickets discussion, but its relevance becomes clear when viewed through the lens of the mechano-osteogenic pathway. Weight-bearing yoga postures — standing poses, balancing poses, and transitions that require supporting full body weight on legs — generate the compressive and tensile forces that stimulate osteoblast activity and bone mineral deposition. For children and adolescents recovering from rickets, whose bones have been structurally compromised and who may have limited confidence in their bodies, yoga offers weight-bearing exercise alongside breathing-based proprioceptive training that is accessible and low-injury-risk.

A randomized trial by Motorwala et al. (published in Osteoporosis International, 2016) demonstrated significant improvements in bone mineral density at the lumbar spine and femoral neck in postmenopausal women with osteopenia following 6 months of structured yoga practice. While this is a different population from pediatric rickets, the underlying mechano-sensing biology is identical: bone responds to load by building more bone, regardless of patient age. Evidence in pediatric bone disease specifically remains limited.

For children with active rickets, the key is progression — beginning with gentle supported standing poses and gradually increasing weight-bearing duration as bone strength improves with treatment. A certified yoga therapist familiar with bone conditions can create an appropriate modification protocol. Avoid deep forward folds and poses that place significant axial load on softened vertebrae during acute active rickets. Three to four sessions per week of 20–30 minutes, emphasizing standing balance poses, hip-hinge movements, and gentle squatting, is a practical entry protocol. Benefits to balance and proprioception reduce fracture risk from falls — a meaningful secondary benefit in children with bone fragility.

Conclusion

Rickets is not a single biochemical failure — it is a breakdown that can occur at any point in the chain from vitamin D absorption through enzymatic activation, receptor function, phosphate regulation, and mineral deposition into bone matrix. The seven biomarkers in this article let you locate exactly where that breakdown is happening, right now, with available and affordable testing. The seven genetic variants explain why some individuals are structurally predisposed to that failure, and how to compensate for each specific impairment.

The most valuable next step is to request a comprehensive panel — 25-OH vitamin D, calcitriol, PTH, serum phosphate, calcium, ALP, and ideally FGF23 — rather than the single vitamin D test that typically gets ordered in isolation. If phosphate is low with normal PTH, genetic testing for PHEX and FGF23 belongs in the conversation. If ALP is low rather than high, hypophosphatasia should be ruled out before any standard rickets treatment is started.

Bring this information to a pediatric endocrinologist, a metabolic bone specialist, or a physician comfortable with the full diagnostic picture. Better questions lead to better answers, and better answers change the trajectory of this condition more than any single supplement.